Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.10) by 0.91 percent. This is a 263.33 percent decrease over losses of $(0.30) per share from the same period last year.
Athersys, Inc. Announces $3.7M Registered Direct Offering Of 3.685M Shares Of Common Stock And Warrants At A Price Of $1/Share And Concurrent Private Placement, Warrants Will Have Excersize Price Of $0.96/Share
Athersys, Inc. (NASDAQ:ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the "Shares") of the Company's common stock (or common stock
